Vertex Pharmaceuticals (VRTX) Change in Acquisitions & Divestments (2009 - 2026)

Vertex Pharmaceuticals' Change in Acquisitions & Divestments history runs 18 years deep, the most recent figure standing at $2.2 billion for Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments rose 34.9% year-over-year to $2.2 billion; the TTM figure through Mar 2026 stood at $587.5 million (down 89.11% YoY), while the FY2025 annual figure was $16.0 million, down 99.64% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $2.2 billion, up from -$4.8 billion in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $2.2 billion in Q1 2026, with the low at -$4.8 billion in Q4 2025.
• The 5-year median for Change in Acquisitions & Divestments is $525.9 million (2023), against an average of $497.0 million.
• The sharpest annual moves came in 2024 and 2025: Change in Acquisitions & Divestments soared 2522.17% in 2024, then sank 428.01% in 2025.
• Vertex Pharmaceuticals' Change in Acquisitions & Divestments stood at $484.1 million in 2022, then slumped by 54.95% to $218.1 million in 2023, then jumped by 569.51% to $1.5 billion in 2024, then tumbled by 428.01% to -$4.8 billion in 2025, then surged by 146.12% to $2.2 billion in 2026.
• Business Quant data shows VRTX's Change in Acquisitions & Divestments at $2.2 billion in Q1 2026, -$4.8 billion in Q4 2025, and $1.3 billion in Q3 2025.